Selara (ustekinumab) is a prescription medicine approved for the management of specific chronic inflammatory conditions. Its use is focused on reducing symptoms and supporting disease control across its approved therapeutic domains.

Selara is indicated for adult patients with:

• Plaque Psoriasis (PsO): To address moderate to severe plaque psoriasis in individuals who may be candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis (PsA): To manage active psoriatic arthritis, which may be used alone or in combination with methotrexate.
• Crohn's Disease (CD): For the care of moderately to severely active Crohn's disease.
• Ulcerative Colitis (UC): For the treatment of moderately to severely active ulcerative colitis.

The medication is also utilized in pediatric patients aged 6 years and older for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. Selara serves as a long-term maintenance therapy for these conditions, helping to achieve and sustain symptom relief and improve patient well-being as part of a treatment plan.

---

Quick Facts: Selara Therapeutic Domains

Condition	Treatment Focus
Plaque Psoriasis	Addresses moderate to severe symptoms
Psoriatic Arthritis	Supports management of active joint and skin disease
Crohn's Disease	Used for moderately to severely active symptoms
Ulcerative Colitis	Supports control of moderately to severely active inflammation

---

Selara (Ustekinumab) eligibility is determined by regulatory agencies based on age, existing health status, and other concurrent conditions.

Contraindications and Restrictions

Selara must not be used by patients who have a clinically significant hypersensitivity to the drug or any of its components. It is also contraindicated in patients with a clinically important active infection, including active tuberculosis; treatment must not be initiated until the infection resolves.

Conditional use is required for patients with latent tuberculosis, who must initiate anti-TB therapy prior to beginning treatment. Patients must also avoid live vaccines during Selara therapy.

---

Population Eligibility Rules

Population Group	Eligibility Status (as stated in label)
Adults ( ge 18 years)	Allowed for all approved indications.
Pediatric Patients ( ge 6 years)	Allowed for Psoriasis and Psoriatic Arthritis.
Children < 6 years	Use not established; safety and efficacy data are insufficient.
Renal/Hepatic Impairment	Not studied; no dose recommendations can be made.
Pregnancy/Lactation	Caution advised; use is not recommended unless clearly needed (Pregnancy exposure registries are available).

Older adults ( ge 65 years) may use Selara without dose adjustment, though caution is recommended due to the generally higher incidence of infections in this group.

The interaction profile for Selara (ustekinumab) is characterized by constraints related to concurrent use of vaccines and other immunosuppressive therapies, as officially documented in regulatory labels.

Formal Contraindications and Restrictions

Interaction Type	Interacting Products	Official Constraint
Pharmacodynamic Contraindication	Live viral or live bacterial vaccines (e.g., BCG, MMR, nasal-spray flu)	Co-administration is prohibited due to the risk of infection and diminished vaccine efficacy.
Timing-Based Restriction	BCG Vaccine	Must not be given during treatment, for one year prior to initiating Selara, or for one year following its discontinuation.
Use with Caution	Other Immunosuppressive agents or biologics	Official regulatory information notes a potential for additive immunosuppression and an increased risk of serious infection.

Exposure-Modifying Interactions

No impact on Selara clearance has been observed with concomitant use of conventional immunosuppressants, such as Methotrexate, NSAIDs, or corticosteroids, according to population pharmacokinetic analyses. However, due to the theoretical potential for Selara to affect cytokine-mediated changes in CYP450 enzyme formation, monitoring of plasma levels is required for certain co-administered drugs. This applies to agents like Warfarin and Cyclosporine, whose concentrations may be indirectly affected, necessitating drug level surveillance by a healthcare provider. Non-live vaccines may be administered, but their ability to generate a protective immune response may be reduced.

Selective Antagonism of the Mineralocorticoid Receptor

Selara's mechanism involves selective competitive antagonism of the Mineralocorticoid Receptor (MR). The drug binds directly to the MR, preventing the endogenous hormone aldosterone from activating the receptor. This action interrupts the downstream signaling required for gene transcription in all target cells, including those in the kidney and the cardiovascular system.

Modulation of Fluid and Tissue Structure

The receptor blockade initiates two primary mechanistic cascades. In the kidney (epithelial tissue), the inhibition of MR signaling halts the reabsorption of sodium ( Na^+) and water, which results in the loss of fluid volume while simultaneously promoting the conservation of potassium ( K^+). This mechanism results in a net decrease in circulating fluid volume. In the heart and blood vessels (non-epithelial tissue), the antagonism interrupts cascades linked to inflammation and fibrosis, which prevents MR-mediated adverse changes in tissue structure.

Mechanism Dynamics

The full physiological consequences of this mechanism, including the non-epithelial actions, require time to manifest as they involve changes in gene expression and protein turnover. The drug's capacity to modulate Na^+ and water balance is constrained by the underlying function of the kidneys and is functionally limited in conditions where the body's potassium status is already elevated.

How to use Selara

Selara (ustekinumab) is administered through subcutaneous injection or intravenous infusion, with the route and dosage schedule determined by the specific condition and the patient’s body weight.

Adult Dosing and Route

Indication	Initial Dose & Route	Maintenance Dose & Route	Frequency
Psoriasis & Psoriatic Arthritis	45 mg or 90 mg SC (based on weight le 100 kg or >100 kg) at Week 0	45 mg or 90 mg SC	Every 12 weeks after Week 4
Crohn’s Disease & Ulcerative Colitis	Weight-based IV infusion (260 mg, 390 mg, or 520 mg)	90 mg SC	Every 8 weeks after the initial IV dose

Special Conditions and Preparation

• Intravenous Infusion: The intravenous dose for Crohn’s Disease and Ulcerative Colitis must be diluted by a healthcare professional prior to administration and infused over a period of at least one hour.
• Subcutaneous Injection: Injections are typically administered at Weeks 0 and 4, followed by the maintenance schedule. The injection site, such as the thigh or abdomen, should be rotated for each dose.
• Pediatric Patients: Patients 6 years of age and older with Plaque Psoriasis or Psoriatic Arthritis receive subcutaneous weight-based dosing at Weeks 0 and 4, then every 12 weeks thereafter. Patients weighing less than 60 kg receive a dose of 0.75 mg/kg.

Note: If a dose is missed, patients should follow the guidance provided by their prescribing physician to ensure the correct treatment frequency is re-established.

Selara (ustekinumab) is a biologic medication that has been studied across several chronic inflammatory conditions. Clinical research has primarily focused on its use in moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Plaque Psoriasis

Clinical trials involving adults with moderate to severe plaque psoriasis have compared ustekinumab to placebo and other active treatments. The main measure of assessment focused on the proportion of patients achieving significant improvement in symptom scores (e.g., a ge 75% reduction) after 12 weeks.

• In two major studies, a significantly greater proportion of patients receiving ustekinumab achieved this level of skin improvement compared to those on placebo (approximately 69% vs. 3%).
• Longer-term follow-up showed that clinical improvement was observed to be maintained in a majority of patients with continuous treatment over a period of five years.

Inflammatory Bowel Disease (IBD)

Evidence for Selara in IBD includes randomized, placebo-controlled trials for both Crohn's disease and ulcerative colitis.

• Crohn's Disease: Induction studies showed that a single intravenous dose led to a higher rate of clinical response at week 6 compared to placebo, including in patients who had an inadequate response to prior anti-TNF therapies. Maintenance studies indicated that a substantial portion of responders achieved and sustained clinical remission at one year of follow-up.
• Ulcerative Colitis: Similar trials for ulcerative colitis demonstrated that intravenous induction and subcutaneous maintenance were associated with higher rates of clinical remission and mucosal improvement at the one-year mark when compared to placebo groups. In the maintenance phase, data showed that 45% of patients receiving ustekinumab were in clinical remission after one year, compared to 26% of those receiving placebo.

General Safety Profile

Across all indications, the most commonly reported adverse events in clinical trials included nasopharyngitis, upper respiratory tract infections, and headache. Ustekinumab, as an immunosuppressant, has been associated with an increased risk of serious infections and a theoretical risk of malignancy, consistent with the mechanism of action of this class of medication.

Common questions about Selara (FAQ)

Q: How quickly should I expect to feel the effects of Selara?

A: Clinical studies on Selara for Crohn’s disease have shown a clinical response in some patients as early as Week 3 to Week 6 following the initial intravenous dose. However, the time it takes to notice improvement can vary widely among individuals.

Q: What is the typical time frame to see the full benefits of Selara?

A: The timeframe to reach the clinical endpoints assessed in trials varies by condition. For skin diseases like psoriasis, significant improvement is often assessed at around 12 weeks. For chronic conditions like inflammatory bowel disease, clinical remission is often assessed in maintenance studies, demonstrating sustained benefit after approximately one year.

Q: Does Selara cause weight gain or weight loss?

A: Official product information does not list significant changes in body weight (gain or loss) as common adverse reactions. However, any unexpected or concerning side effects should be brought to the attention of a healthcare professional.

Q: Can Selara affect my mood or sleep patterns?

A: Official regulatory documents list Depression as a rare serious side effect that has been reported. Changes in sleep patterns are not explicitly listed as a side effect. Any changes in mood or sleep patterns should be reported to a healthcare provider.

Q: What happens if I forget to take a dose of Selara?

A: If a dose is missed, official guidance instructs patients to contact their prescribing physician to determine the appropriate next steps. They will advise on when the dose should be administered to help re-establish the correct treatment schedule.

Q: How does Selara compare to other treatments for the same condition?

A: Selara is one of several treatments available for chronic inflammatory conditions. Clinical trials have demonstrated its effectiveness in patients who have previously had an inadequate response to, or were intolerant of, other therapies, including anti-TNF treatments, offering a distinct treatment option.

Q: Is Selara a biologic drug or a traditional pill?

A: Selara's active ingredient, ustekinumab, is classified as a biologic drug, which is a medicine made from living organisms. It is administered through subcutaneous injection or intravenous infusion, not as a traditional oral pill.

Q: How long does Selara stay in your system after stopping treatment?

A: The time it takes for a drug to be eliminated from the body is measured by its half-life. Selara has an estimated terminal elimination half-life ranging from approximately 15 to 32 days.

Q: Are the side effects of Selara worse when you first start taking it?

A: The regulatory label does not provide a general statement on whether side effects are more severe at the start of treatment. Common effects like headache and fatigue have been reported during the treatment period.

Q: Can taking Selara make you more sensitive to the sun?

A: While the drug is associated with a risk of non-melanoma skin cancer, the official regulatory label does not explicitly list photosensitivity. It is important to discuss all concerns with a healthcare provider.

Q: What are the signs that Selara is actually working for me?

A: In clinical trials, efficacy was measured by achieving a significant reduction in symptoms (such as skin clearance) or achieving clinical remission and mucosal improvement (for inflammatory bowel disease) at specific time points.

Q: Can Selara be used if I have kidney or liver issues?

A: Official studies have not been conducted to specifically evaluate Selara in patients with severe renal (kidney) or hepatic (liver) impairment. Because of this, no specific dose recommendations are available for these populations.

Q: Why would a doctor choose to prescribe Selara instead of a similar drug?

A: The regulatory status supports Selara as a treatment for patients who have had an inadequate response to or were intolerant of prior treatments. The drug's distinct mechanism of action is part of the clinical considerations for its use.

Q: Is there a generic version of Selara available?

A: Selara (ustekinumab) is a biologic drug. Official regulatory agencies have approved, or are reviewing, biosimilar products to Selara. Biosimilars are highly similar versions of the original biologic.

Q: What is the experience like for patients who have been on Selara long-term?

A: Long-term extension studies, lasting up to five years, have found that clinical improvement and remission were maintained in a majority of patients who continued treatment. The overall safety profile remained generally consistent during this time.

Q: Does Selara affect fertility?

A: Limited human and animal data did not suggest an adverse effect on male or female fertility. Reproductive health should be discussed with a healthcare provider.

Q: Are there any common over-the-counter medications that interact with Selara?

A: Regulatory information indicates that common over-the-counter pain relievers that are classified as Nonsteroidal Anti-inflammatory Agents (NSAIDs) have not been observed to impact how Selara is cleared from the body.

Q: Is it okay to use pain relievers like ibuprofen or acetaminophen while on Selara?

A: Official product information states that NSAIDs (a drug class including ibuprofen) do not affect how Selara is cleared from the body. Official product information on drug interactions focuses primarily on NSAIDs and does not include specific safety data for acetaminophen.

Q: Is Selara effective for all stages of the condition it treats?

A: Selara is specifically indicated for the treatment of moderate to severe plaque psoriasis, Crohn’s disease, and ulcerative colitis, as well as for active psoriatic arthritis. It is not indicated for mild forms of these conditions.

How to Store and Dispose of Selara (Eplerenone)

All storage and disposal procedures for Selara film-coated tablets must strictly adhere to instructions provided in regulatory labeling.

Storage Conditions

Selara tablets do not require any special storage conditions. The product is stable at room temperature, typically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C. The medicine must be kept in the original container to maintain its stability and should always be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired Selara tablets must be conducted in accordance with local requirements for pharmaceutical waste. The preferred method is typically a drug take-back program. The tablets should not be flushed down the toilet or poured down a sink.